Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Trotta, F.
Right arrow Articles by Sun, L.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trotta, F.
Right arrow Articles by Sun, L.-Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 1999; 38: 1007-1009
© 1999 British Society for Rheumatology

Case Report

Long-lasting remission and successful treatment of acquired factor VIII inhibitors using cyclophosphamide in a patient with systemic lupus erythematosus

F. Trotta, G. Bajocchi, R. La Corte, S. Moratelli1 and L.-Y. Sun2

Division of Rheumatology, Arcispedale S. Anna,
1 Centre for the Study of Thrombosis and Haemostasis, University of Ferrara, Italy and
2 Department of Immunology, Gu Lou Hospital, Nanjing, China

Correspondence to: G. Bajocchi, Divisione di Reumatologia, Arcispedale S. Anna, Cozso Giovecca 203, 44100 Ferrara, Italy.

Acquired deficiency of clotting factor VIII (FVIII) is a rare bleeding diathesis seldom encountered in systemic lupus erythematosus (SLE). Reduction of FVIII activity by autoantibodies can cause potentially life-threatening situations. Herein, an SLE patient with a positive lupus anticoagulant (LAC) test who abruptly developed metrorrhagia 4 yr after diagnosis is reported. Coagulation tests revealed FVIII activity reduced to 3% and a prolonged aPTT. FVIII inhibitor(s) were found to be as high as 3.0 Bethesda Units. Plasmapheresis, immunoglobulins, prednisolone and FVIII plasma concentrates induced the cessation of metrorrhagia, but the clotting tests were barely improved. One month later, extensive ecchymosis appeared and worsened, despite re-administration of the previous therapy. Pulse cyclophosphamide followed by oral administration was then started with normalization of coagulation parameters and long-lasting disease remission.

KEY WORDS: Systemic lupus erythematosus, Factor VIII, Acquired deficiency, Metrorrhagia, Treatment, Cyclophosphamide.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
M. Franchini and G. Lippi
Acquired factor VIII inhibitors
Blood, July 15, 2008; 112(2): 250 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
O. Beyne-Rauzy, F. Fortenfant, and D. Adoue
Acquired haemophilia and PM-Scl antibodies
Rheumatology, August 1, 2000; 39(8): 927 - 928.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.